Logo

Definiens and BioImage Pen High-Content Screening Alliance

Dec 06, 2004

NEW YORK, Dec. 6 (GenomeWeb News) - Definiens and BioImage will co-market their products for high-content cell-based screening assays, and co-develop applications in this area, the companies said today.

 

Under the non-exclusive deal, the companies will co-market Definiens' Cellenger software for automated image analysis and BioImage's Redistribution cell-based pathway screenings assays, which measure protein translocation.

 

In addition, Definiens, based in Munich, Germany, and BioImage of Copenhagen, Denmark, plan to co-develop specific applications for high-content screening.

Breaking News
The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.